Rigel Pharmaceuticals (RIGL) Operating Income Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.22% |
| Dec 31, 2025 | 26.43% |
| Sep 30, 2025 | 32.36% |
| Jun 30, 2025 | 40.70% |
| Mar 31, 2025 | -9.49% |
| Dec 31, 2024 | 24.24% |
| Sep 30, 2024 | 25.94% |
| Jun 30, 2024 | 15.11% |
| Mar 31, 2024 | 17.64% |
| Dec 31, 2023 | -4.93% |
| Sep 30, 2023 | 28.78% |
| Jun 30, 2023 | 27.40% |
| Mar 31, 2023 | 12.45% |
| Dec 31, 2022 | 15.77% |
| Sep 30, 2022 | -0.61% |
| Jun 30, 2022 | 7.69% |
| Mar 31, 2022 | -10.14% |
| Dec 31, 2021 | -6.29% |
| Sep 30, 2021 | 2.74% |
| Jun 30, 2021 | 0.90% |
| Mar 31, 2021 | 34.35% |
| Dec 31, 2020 | -8.11% |
| Sep 30, 2020 | -15.24% |
| Jun 30, 2020 | -4.47% |
| Mar 31, 2020 | 25.82% |
| Dec 31, 2019 | 4.97% |
| Sep 30, 2019 | 10.57% |
| Jun 30, 2019 | 3.47% |
| Mar 31, 2019 | 3.87% |
| Dec 31, 2018 | 16.54% |
| Sep 30, 2018 | -0.37% |
| Jun 30, 2018 | -2.67% |
| Mar 31, 2018 | 0.77% |
| Dec 31, 2017 | -0.46% |
| Sep 30, 2017 | 6.93% |
| Jun 30, 2017 | 4.91% |
| Mar 31, 2017 | 7.02% |
| Dec 31, 2016 | 9.43% |
| Sep 30, 2016 | -4.74% |
| Jun 30, 2016 | 8.74% |
| Mar 31, 2016 | 3.38% |
| Dec 31, 2015 | 8.31% |
| Sep 30, 2015 | -16.38% |
| Jun 30, 2015 | -20.28% |